U.K. switches benzocaine, nicotine sprays
This article was originally published in The Tan Sheet
The country's Medicines and Healthcare Products regulatory Authority switches benzocaine throat spray (1 mg) to general sale (similar to OTC in the U.S.) in the U.K. to relieve sore throat pain in adults and children 6 years and older. The regulatory agency March 24 also switched nicotine nasal spray, including McNeil's Nicorette nasal spray, to general sale to help consumers older than 12 stop smoking
You may also be interested in...
EU Regulatory Round-Up, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty
Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.
Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.
Fresenius Kabi and Vifor Pharma have agreed to create a joint venture in China for intravenous iron products.